Jessica Kim Cohen February 14, 2020 09:00 Am
Lack of CMS monitoring allowed some pharmacies
to use beneficiaries' Medicare Part D eligibility information for inappropriate
reasons, including for marketing purposes, HHS' Office of Inspector General
said Friday.
Pharmacy providers in question were taking
advantage of "gaps" in a system to verify Part D eligibility,
according to the OIG
report.
The OIG audited 30 organizations that submitted
particularly large volumes of E1 transactions—the transactions pharmacies
submit to verify a beneficiary's enrollment in the Medicare Part D prescription
drug program—from 2013 to 2015. Those organizations included mail-order
pharmacies, retail pharmacies, doctor's offices, clinics and other entities
that dispense prescription drugs and submit prescriptions to payers for
reimbursement.
It wasn't a random sample. The OIG selected 30
organizations that had submitted large volumes of E1 transactions compared to
the number of prescriptions they processed.
Pharmacy providers submit an E1 transaction to
retrieve beneficiary information needed to bill a prescription to a Part D
insurance plan. They're meant to be submitted when a beneficiary doesn't have
their Part D plan card.
When used appropriately, a pharmacy submits its
national provider identifier and a beneficiary's demographic information to a
CMS contractor, which forwards the request to a facilitator. The facilitator
responds with the beneficiary's Part D coverage information, so that the
pharmacy call bill their plan and other payers.
But the OIG found that 25 of the 30 pharmacy
providers in its audit were using Part D eligibility information for purposes
other than determining drug coverage or billing for a prescription.
Almost all—98%—of those 25 companies' E1
transactions weren't associated with a prescription, suggesting they were used
for inappropriate purposes, according to the OIG. In total, the OIG was unable
to link 2.6 million of the 3.9 million E1 transactions submitted by the 30
companies to a prescription.
The OIG contacted 15 of the 25 providers to
request information on whether they had submitted appropriate transactions. Ten
of the companies were closed or under investigation.
The OIG initiated its investigation after the
CMS requested it audit one mail-order pharmacy's E1 transactions. That pharmacy
was one of the 30 organizations included in the audit.
Organizations included in the audit used Part D
eligibility information to evaluate marketing leads and allowed marketing
companies to submit E1 transactions using their national provider identifier,
among other inappropriate uses. That could include allowing marketing companies
to submit E1 transactions for contracted telemarketing services.
One pharmacy provider told the OIG that they had
agreements with six different marketing companies, which submitted more than
100,000 E1 transactions without authorization.
That's particularly concerning since E1
transactions contain protected health information.
"This practice of granting telemarketers'
access to E1 transactions or using E1 transactions for marketing purposes puts
the privacy of the beneficiaries' PHI at risk," the OIG wrote.
Other inappropriate uses included using E1
transactions to learn about a beneficiary's private insurance coverage, so that
the provider could bill for items not covered by Medicare.
The OIG said inappropriate use of eligibility
information was able to occur because the CMS hadn't yet implemented
comprehensive controls to monitor companies submitting a high number of E1
transactions. The CMS has since started monitoring providers more closely, and
has denied E1 transaction access for 20 of the 30 organizations in the OIG's audit
sample.
Other recommendations from the OIG included
suggesting the CMS publish clear guidance outlining appropriate use of E1
transactions.
The CMS said it agreed with the OIG's
recommendations and has already taken steps to better ensure pharmacy providers'
compliance.
"CMS is committed to ensuring Part D
covered providers use E1 transactions in the appropriate manner," the
agency wrote to the watchdog.
No comments:
Post a Comment